The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | Highlights from WCLC 2021
“Cancer does not stop with COVID-19 and therefore the science needs to continue” says Bob Li, MD, PhD, MPH, Memorial Sloan Kettering Cancer Center, New York, NY, discussing the key trial updates from this year’ virtual WCLC 2021. He highlights the TALENT study, investigating a novel screening approach in lung cancer, as a key contribution likely to impact clinical practice in the future. Additionally, attempts to bring successful therapies forward in the treatment paradigm to early-stage lung cancer were seen, including the LCMC3 and ITACA trials. Dr Li also notes the emergence of antibody-drug conjugates, including trastuzumab deruxtecan, likely to grow into a successful new class of drugs for lung cancer. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
